The anti-angiogenic activity of SHP2 inhibitors has recently been suggested in mouse tumor models40,41; however, the direct genetic evidence to demonstrate the role of SHP2 in angiogenesis, particularly in tumor angiogenesis, require investigation. This evidence concerns the gene PTPN11 and neoplasm.